# Podcast Episode Description
**Wegovy's Big Expansion: New Pill Approval, MASH Treatment in India, and Safety Questions Explained**
Wegovy is having a landmark moment — and this episode breaks down everything you need to know. From a historic European Commission approval of the first-ever oral GLP-1 weight loss pill to a game-changing new use in India for treating liver disease, Novo Nordisk is rapidly transforming Wegovy from a single injectable drug into a multi-product global platform.
In this episode, we cover:
✅ **The first oral Wegovy pill approved in the EU** — 25mg semaglutide tablet showing ~17% average weight loss in trials, compared to 3% for placebo
✅ **A new higher-dose 7.2mg Wegovy injection** approved in Europe for patients needing stronger weight loss results
✅ **India's landmark approval** of Wegovy injection for MASH (metabolic dysfunction-associated steatohepatitis), a serious fatty liver disease — making it the first GLP-1 therapy approved for this condition in India
✅ **Safety updates you need to know**, including a potential link between Wegovy and a rare eye condition (ischemic optic neuropathy), plus new FDA findings that clear GLP-1 drugs of suicidal ideation risk
✅ **Supply chain relief** — Wegovy shortages have officially eased, according to FDA data
✅ **A new Medicare bridge program** launching in 2026 that could reshape insurance access to Wegovy for weight management
✅ **How Wegovy stacks up** against a growing wave of competing oral obesity drugs entering the market
Whether you're a patient, healthcare provider, investor, or just curious about the future of obesity medicine, this episode unpacks why Wegovy continues to dominate headlines — and what its expansion means for pricing, competition, and patient access worldwide.
**Perfect for listeners interested in:** pharmaceutical news, obesity treatment,
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
